RetinaRisk

RetinaRisk, founded in 2008 and headquartered in Iceland, aims to revolutionize diabetic eye health through risk stratification and personalized care. The company's clinically validated RetinaRisk algorithm empowers people living with diabetes, providing a more streamlined and personalized healthcare experience. The RetinaRisk app enables the global diabetic population of 463 million to calculate and better understand their individualized risk of developing sight-threatening eye diseases that could lead to blindness.

The $500.00K Venture Round investment received at 10 July 2020 from Iceland Venture Studio further propels RetinaRisk's mission. Founded by Prof. Einar Stefansson and Dr. Arna Gudmundsdottir, who together possess over 30 years' experience in screening for diabetic retinopathy and treating diabetes, the RetinaRisk algorithm has been clinically validated in over 25,000 diabetic patients in five countries, showcasing its robustness. More details on the research findings can be found on their website.

With a focus on wellness, prevention, and personalization through digital engagement and predictive analytics, RetinaRisk aligns with the evolving landscape of digital health. By empowering patients to become more knowledgeable and active participants in their wellness journey, the company offers a truly personalized approach, ensuring the right patient receives the right treatment at the right time.

RetinaRisk's innovation extends to its API solution, serving as a decision support tool for healthcare professionals to enhance the clinical safety of patients, identify high-risk individuals, and streamline diabetic retinopathy eye screening, making it more efficient and cost-effective for hospitals and national healthcare systems.

For more information, visit their website.